Floxuridine, Dexamethasone, and Irinotecan After Surgery in Treating Patients With Liver Metastases From Colorectal Cancer
Part of paid clinical trials in New York, New York.
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Study ID
- NCT00003753
- Phase
- PHASE2
- Status
- Completed
Conditions
- Colorectal Cancer
- Metastatic Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- dexamethasone — DRUG
- floxuridine — DRUG
- irinotecan hydrochloride — DRUG
- adjuvant therapy — PROCEDURE
- conventional surgery — PROCEDURE
Study Details
RATIONALE: Drugs used in chemotherapy, such as floxuridine, dexamethasone, and irinotecan, use different ways to stop tumor cells from dividing so they stop growing or die. Hepatic arterial infusion uses a catheter to deliver chemotherapy directly to the liver. Combining more than one drug and giving them in different ways may kill any tumor cells remaining after surgery. PURPOSE: Phase II trial to study the effectiveness of irinotecan combined with hepatic arterial infusion with floxuridine and dexamethasone after surgery in treating patients who have liver metastases from colorectal cancer.
Key Dates
- Start date
- Sep 30, 1998
- Status verified
- Jun 2013
- Primary completion
- Apr 30, 2004
- Completion
- Apr 30, 2004
Study Design
- Primary purpose
- TREATMENT
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Memorial Sloan-Kettering Cancer Center | New York | New York | 10021 | - |
Find similar trials in New York, NY
By condition
By specialty
By research site
Related Studies
- A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid TumorsPHASE1/PHASE2 · Recruiting · Merus B.V. · La Jolla, California
- Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC FusionsPHASE1/PHASE2 · Recruiting · IDEAYA Biosciences · Los Angeles, California
- Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal MetastasesPHASE1/PHASE2 · Recruiting · Roswell Park Cancer Institute · Buffalo, New York
- Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid TumorsPHASE1 · Recruiting · Bicara Therapeutics · La Jolla, California